S2343 Efficacy and Safety of Sintilimab in Patients With Gastric or Gastroesophageal Junction Cancer: A Systematic Review and Meta-Analysis

作者
Faryal Altaf,Eeshal Fatima,Mikail Khanzada,Adnan Safi,Zaheer Ahmad Qureshi
出处
期刊:The American Journal of Gastroenterology [Lippincott Williams & Wilkins]
卷期号:119 (10S): S1679-S1679
标识
DOI:10.14309/01.ajg.0001038740.64570.ec
摘要

Introduction: Gastric cancer is the 5th most common cancer worldwide. The majority of patients are diagnosed at advanced stages when relying just on surgery may not be adequate because, despite surgical resection, the prognosis remains poor, and most patients relapse after surgery. Immune checkpoint inhibitors such as anti-programmed cell death protein-1/programmed death-ligand 1 (PD-1/PD-L1) antibodies are primarily approved for the treatment of inoperable or metastatic solid cancers. Sintilimab is a highly selective monoclonal anti-PD-1/PD-L1 antibody with a robust anti-tumor response. The primary aim of this study is to assess the efficacy and safety of sintilimab in gastric or gastro-esophageal junction cancer. Methods: A thorough search was conducted on PubMed, Scopus, and Google Scholar from inception till May 2024. OpenMeta[Analyst] was used to perform statistical analysis. The pooled disease control rate, objective response rate, stable disease rate, and partial disease rate with 95% confidence interval (CI) were assessed using the random-effects model. Heterogeneity was evaluated using the Higgins I2 index. In all cases, P-value < 0.05 was indicative of significant results. This review has been registered with PROSPERO (CRD42024521560). Results: A total of 16 studies, consisting of 932 patients who received sintilimab therapy, were included in our study (Table 1). The majority of the patients (649) were male. The mean age of the participants ranged from 21 to 86 years. The pooled proportion revealed a disease control rate of 73% (95% CI = 66.2% - 79.3%; P-value < 0.001), an objective response rate of 40% (95% CI = 24.3% - 57.2%; P-value < 0.001), and a stable disease rate of 34.6% (95% CI = 22.8% - 47.4%; P-value < 0.001), and a partial disease rate of 31.6% (95% CI = 18.1% - 45.1%; P-value < 0.001). However, high heterogeneity was observed. Commonly reported adverse events included anemia, neutropenia, vomiting, and an increase in the levels of liver enzymes, but none of these adverse events showed a significant association with sintilimab therapy. Conclusion: Sintilimab shows promising efficacy and a well-tolerated safety profile. Our results suggest its potential as an innovative therapeutic option for individuals with gastric or gastro-esophageal junction cancer; however, significant heterogeneity was observed in some results, making it difficult to come to a solid conclusion. Therefore, large-scale randomized trials are required to confirm our findings. Table 1. - Characteristics of the included studies Study Name Year Type of Study Participants (n) Age (years)* Intervention Jiang et al. 2022 Single-arm Phase 2 Study 36 65.5 (43-76) Sintilimab + Oxaliplatin + Capecitabine Xu et al. 2023 Phase 3 RCT 327 62 (55-67) Sintilimab + Chemotherapy (Capecitabine + Oxaliplatin) Wei et al. 2023 Single-arm Phase 2 Trial 34 65.5 (58-68) Sintilimab + Chemoradiotherapy (nab-paclitaxel) Ding et al. 2022 Prospective Study 30 62 (30-75) Sintilimab + XELOX Chemotherapy Zhang et al. 2023 Single-arm Phase 2 Trial 30 59 (28-73) Sintilimab + Apatinib + Chemotherapy (Irinotecan + Paclitaxel) Wang et al. 2022 Single-center Retrospective Study 39 64 (41-78) Sintilimab + Chemotherapy (nab-paclitaxel) Jiang et al. 2020 Open label Phase 1b study 20 59.8 (36.9-69.3) Sintilimab + Chemotherapy (Capecitabine + Oxaliplatin) Wang et al. 2021 Retrospective Study 37 62 (21-86) Sintilimab Li et al. 2024 Prospective Cohort Study 32 58 (43-70) Sintilimab + Chemotherapy (FLOT) Hou et al. 2023 Retrospective Study 52 64 (30–77) Sintilimab + apatinib oral Nie et al. 2021 Retrospective Study 52 64 (30–80) Sintilimab + chemotherapy (apatinib, trastuzumab, or nab-paclitaxel) Guo et al. 2022 Single-arm Phase 2 Trial 30 62 (30–72) Sintilimab + XELOX regimen Gao et al. 2023 Retrospective Study 34 61 (39–73) Sintilimab (combined with apatinib) Huang et al. 2023 Retrospective Study 75 64 (31–75) Sintilimab Huang et al. 2022 Retrospective Study 48 59 (28-81) Sintilimab combined with chemotherapy Zhou et al. 2023 Single-arm Phase 2 Trial 56 18-75** Sintilimab and nabpaclitaxel

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
Xiangguang发布了新的文献求助10
1秒前
start完成签到,获得积分10
1秒前
SciGPT的应助被阿飞采纳,获得10
1秒前
欢呼的若完成签到,获得积分10
1秒前
1秒前
2秒前
DW的应助被cloudss采纳,获得10
2秒前
常想一二发布了新的文献求助10
2秒前
2秒前
2秒前
zzZ5发布了新的文献求助10
2秒前
cdercder的应助被小巧的箴采纳,获得10
2秒前
Sss发布了新的文献求助10
2秒前
3秒前
3秒前
予秋发布了新的文献求助10
3秒前
4秒前
4秒前
4秒前
WYL发布了新的文献求助10
4秒前
WYL发布了新的文献求助10
4秒前
清脆问柳完成签到 ,获得积分10
4秒前
空隙可欣完成签到,获得积分10
4秒前
kkk完成签到 ,获得积分10
4秒前
禾鱼完成签到,获得积分10
4秒前
4秒前
5秒前
李健的小迷弟的应助被罗龙生采纳,获得10
5秒前
赘婿的应助被未了采纳,获得10
5秒前
开朗含海完成签到,获得积分10
6秒前
星辰大海的应助被董家旭采纳,获得10
6秒前
6秒前
promise完成签到,获得积分10
6秒前
6秒前
所所的应助被SamYang采纳,获得10
6秒前
王白石发布了新的文献求助10
7秒前
7秒前
WYL发布了新的文献求助10
7秒前
WYL发布了新的文献求助10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180586
求助须知:如何正确求助?哪些是违规求助? 9570581
关于积分的说明 21813457
捐赠科研通 7776777
什么是DOI,文献DOI怎么找? 3433294
关于科研通互助平台的介绍 2557547
邀请新用户注册赠送积分活动 2479253